Nuvalent, Inc. (NUVL)

Market Cap	5.47B
Revenue (ttm)	n/a
Net Income (ttm)	-224.29M
Shares Out	71.05M
EPS (ttm)	-3.50
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	293,064
Open	80.72
Previous Close	80.30
Day's Range	76.86 - 80.72
52-Week Range	61.80 - 113.51
Beta	1.31
Analysts	Strong Buy
Price Target	112.36 (+45.96%)
Earnings Date	Feb 25, 2025

About NUVL

Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Ph...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 29, 2021
• Employees: 92
• Stock Exchange: NASDAQ
• Ticker Symbol: NUVL
• Website: https://www.nuvalent.com

Analyst Forecast

According to 11 analysts, the average rating for NUVL stock is "Strong Buy." The 12-month stock price forecast is $112.36, which is an increase of 45.96% from the latest price.

Price Target

$112.36

(45.96% upside)

Analyst Consensus: Strong Buy